AN2 Therapeutics(ANTX)2025-03-25 20:03Financial Performance - Cash, cash equivalents, and investments totaled $88.6 million as of December 31, 2024, expected to fund operations through 2027[1] - Net loss for the full year 2024 was $51.3 million, compared to a net loss of $64.7 million in 2023, representing a 20.5% improvement[9] - Interest income for the full year 2024 was $5.5 million, an increase from $4.9 million in 2023[9] - General and Administrative (G&A) expenses for the full year 2024 were $14.1 million, slightly down from $14.8 million in 2023[9] - Research and Development (R&D) expenses for the full year 2024 were $40.5 million, a decrease of 26.2% from $54.9 million in 2023[9] - Restructuring charges for the full year 2024 amounted to $2.2 million due to severance payments and other employee termination expenses[9] Clinical Development - The company plans to announce topline Phase 3 results for epetraborole in the second quarter of 2025[4] - A Phase 1 clinical study for AN2-502998, targeting Chagas disease, is expected to start in mid-2025[1] - Enrollment in a 200-patient observational trial for melioidosis was completed in October 2024, with a Phase 2 study planned for the second half of 2025[6] - The company aims to advance its first oncology candidate from its boron chemistry platform into development in the second half of 2025[1]